Cigarette smoke exposure up-regulates endothelin receptor B in human pulmonary artery endothelial cells: molecular and functional consequences by Milara Payá, Javier et al.
RESEARCH PAPERbph_979 1599..1615
Cigarette smoke exposure
up-regulates endothelin
receptor B in human
pulmonary artery
endothelial cells:
molecular and functional
consequences
J Milara1,2, JL Ortiz3, G Juan4, R Guijarro5, P Almudever1,2, M Martorell6,
EJ Morcillo2,3,7 and J Cortijo1,2,3
1Research Unit, University General Hospital Consortium, Valencia, Spain, 2CIBERES, Health
Institute Carlos III, Valencia, Spain, 3Department of Pharmacology, Faculty of Medicine,
University of Valencia, Valencia, Spain, 4Respiratory Unit, University General Hospital
Consortium, Valencia, Spain, 5Thoracic Surgery Unit, University General Hospital Consortium,
Valencia, Spain, 6Department of Pathology, University General Hospital Consortium, Valencia,
Spain, and 7Clinical Pharmacology Unit, University Clinic Hospital, Valencia, Spain
Correspondence
Javier Milara, Unidad de
Investigación, Consorcio Hospital
General Universitario, Avenida
tres cruces s/n, E-46014 Valencia,
Spain. E-mail:
xmilara@hotmail.com
----------------------------------------------------------------
Keywords
pulmonary artery endothelial
cells; endothelin receptor B;
bosentan; cigarette smoke;
endothelial dysfunction
----------------------------------------------------------------
Received
16 March 2010
Revised
20 June 2010
Accepted
16 July 2010
BACKGROUND AND PURPOSE
Pulmonary arteries from smokers and chronic obstructive pulmonary disease patients show abnormal endothelium-dependent
vascular reactivity. We studied the effect of cigarette smoke extract (CSE) on endothelin receptor B (ETB) expression in human
pulmonary artery endothelial cells (HPAECs) and its role in endothelial dysfunction.
EXPERIMENTAL APPROACH
ETB receptor expression was measured by real time RT-PCR, Western blot and immunofluorescence. Cell contraction,
intracellular Ca2+, F/G-actin, RhoA activity, myosin light chain phosphorylation, ET, NO, thromboxane (Tx)A2 and reactive
oxygen species (ROS) were measured by traction microscopy, fluorescence microscopy, phalloidin fluorescence, colorimetric
assay, Western blot, ELISA and DCFDA fluorescence respectively.
KEY RESULTS
Cigarette smoke extract dose-dependently increased ETB receptor expression in HPAECs after 24 h incubation. CSE-induced
ETB expression was attenuated by bosentan, the ETB receptor antagonist BQ788, the Rho kinase antagonist Y27632 and the
antioxidant N-acetylcysteine. A monoclonal antibody to ET-1 prevented CSE-induced ETB receptor overexpression. Twenty-four
hour exposure to ET-1 dose-dependently increased ETB receptor expression, mimicking the effect of CSE. CSE-induced ETB
receptor overexpression caused greater cell contraction; increased intracellular Ca2+; increased F/G-actin and RhoA activity;
increased myosin light chain phosphorylation; augmented TxA2 and ROS production; and decreased NO after acute ET-1
(10 nM). These effects were attenuated by bosentan, BQ788, Y27632 and N-acetylcysteine.
CONCLUSIONS AND IMPLICATION
Cigarette smoke extract induced ETB receptor overexpression by a feed forward mechanism mediated partly by ET release,
promoting HPAEC dysfunction and attenuated by ETB receptor blockade, Rho kinase and ROS inhibition. These results provide
support for the use of bosentan in CS-related endothelial dysfunction.
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Introduction
Cigarette smoke (CS) is the major pathogenic factor
implicated in chronic obstructive pulmonary
disease (COPD), and pulmonary hypertension (PH)
develops in approximately 10% of smokers with
COPD (Voelkel and Cool, 2003). Pulmonary arteries
of COPD patients show abnormal endothelium-
dependent vascular reactivity (Dinh-Xuan et al.,
1991; Peinado et al., 1998). Moreover, the endothe-
lial function of pulmonary arteries in healthy
smokers lies between that in non-smokers and
COPD patients, indicating that endothelial dysfunc-
tion is present at early stages of the disease (Peinado
et al., 1998). The impairment of endothelial func-
tion results from changes in the expression and
release of vasoactive mediators that also regulate cell
growth (Wright et al., 2004). Overall, these initial
alterations may lead to progressive changes in the
vascular structure and function that underlie the
development of PH in COPD.
Many studies have shown the deleterious effect
of CS on endothelial function (Santos et al., 2002;
Wright et al., 2004; Milara et al., 2010) coupled with
the expression and release of the pro-inflammatory
cytokines interleukin (IL)-1b, IL-6, IL-8 and tumour
necrosis factor-a. (Wright et al., 2004; Orosz et al.,
2007; Milara et al., 2010). Furthermore, CS promotes
endothelial cell contraction through the activation
of RhoA and myosin light chain (MLC) kinase
leading to increased endothelial cell permeability,
which is an important component in the pathogen-
esis of PH (Bernhard et al., 2005; Morrell et al., 2009;
Richens et al., 2009). CS also impairs nitric oxide
(NO) release from endothelial cells, caused by
CS-derived reactive oxygen species (ROS) inactivat-
ing endothelial NO synthase (eNOS) via the inter-
action of Rho kinase with eNOS (Sugimoto et al.,
2007). Moreover, products derived from CS decrease
vasodilators and anti-mitogenic agents such as NO
and prostacyclin (PGI2) and increase the release of
vasoconstrictors and pro-mitogenic agents, such as
endothelin-1 (ET-1) and thromboxane A2 (TxA2)
thereby promoting endothelial dysfunction and
vascular remodelling (Barua et al., 2003; Wright
et al., 2006; Nana-Sinkam et al., 2007).
Endothelin-1 is a secreted peptide that signals
through two transmembrane G protein-coupled
receptors, ETA and ETB (receptor nomenclature
follows Alexander et al., 2009). These receptors are
both simultaneously expressed in all cell types
studied, with one notable exception; only the ETB
receptor is expressed on endothelial cells (Migneault
et al., 2005).
Under normal conditions endothelial ETB recep-
tors elicit vasodilatation and anti-mitogenic effects
through the release of NO and/or PGI2 in pulmo-
nary endothelial cells and, to a lesser extent,
mediate release of ET-1 and TxA2 (Galie et al., 2004).
In addition, pulmonary ETB receptors also mediate
the pulmonary clearance of circulating ET-1 and the
reuptake of ET-1 by endothelial cells (Dupuis et al.,
1996). Significantly, the role of ETB receptors in PH
induced by hypoxia is well established, as mice with
specific knockout of the endothelial cell ETB recep-
tors present an exaggerated increase in right ven-
tricular pressure during hypoxia (Kelland et al.,
2010). However, CS-induced PH in COPD patients
exhibits characteristics significantly different from
those found in primary hypoxaemic PH patients. In
this context, the number of inflammatory cells infil-
trating the wall of pulmonary arteries correlates
with the enlargement of the intimal layer and
endothelial dysfunction (Peinado et al., 1999). Fur-
thermore, recent studies have shown that the sys-
temic inflammation associated with COPD appears
to increase the risk for developing PH in humans as
well as in in vitro and in vivo models of pulmonary
artery remodelling induced by tobacco smoke
(Eddahibi et al., 2006; Joppa et al., 2006; Stenmark
et al., 2006). Interestingly, ETA and ETB receptors are
up-regulated in bronchial biopsies from COPD
patients and ET-1 is up-regulated in COPD patients
with PH (Moller et al., 1999; Carratu et al., 2008),
which suggest that changes in the ET signalling
system may not be limited to an increased produc-
tion of ET-1. Furthermore, it has been shown
recently that CS mediates the up-regulation of ETA
and ETB in rat bronchial and vascular smooth
muscle cells, thereby increasing their contractility
(Granstrom et al., 2006; Xu et al., 2008). However,
no data have been reported concerning the effect of
CS on ETB receptor expression and the functional
consequences in endothelial cells.
Therefore, we hypothesized that CS, the
main agent involved in COPD and the subsequent
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endothelial dysfunction, may affect ETB receptor
expression in human pulmonary artery endothelial
cells (HPAECs), and that this modulation could
influence HPAEC function. Moreover, we decided to
evaluate bosentan [a putative therapeutic agent
in the treatment of some forms of PH in COPD
(Barbera and Blanco, 2009)], a dual ETA-ETB receptor
antagonist, on the endothelial cell function follow-
ing CS-induced expression of ETB receptors in vitro.
Methods
Isolation and culture of HPAECs
With the approval of the local ethics committee
and informed consent of the patients, peripheral
human lung tissue was obtained from 15 non-
smoker patients (3 women, 12 men (65  4 years)
who were undergoing surgery for lung carcinoma.
None of the patients exhibited clinical evidence
of PH or COPD, and none was chronically treated
with theophylline, b-adrenoceptor agonists, corti-
costeroids or anti-cholinergic drugs. Only macro-
scopically normal segments of artery were used for
our experiments.
We used HPAECs from non-smokers in order
to maximize the in vitro effects of CS. Segments of
pulmonary artery (2–3 mm internal diameter) were
dissected free from parenchyma lung tissue, cut
longitudinally and digested with 1% collagenase
(Gibco, UK) in RPMI-1640 culture medium for
30 min at 37°C. The digestion was neutralized by
adding RPMI 1640 supplemented with 20% fetal calf
serum (FCS), and the homogenate was centrifuged
at 250¥ g for 10 min at 4°C.
The pellet was resuspended, and cells were
cultured in EGM-2 endothelial culture medium
supplemented with Single Quotes (Clonetics, UK),
10% FCS, 1% fungizone and 2% streptomycin/
penicillin.
The selection of HPAECs was performed as
described previously (Hewett and Murray, 1993;
Ortiz et al., 2009), modified to include the use of a
commercially available Dynabeads CD31 endothe-
lial cell kit (Dynal Biotech, Germany). Briefly, cells
were trypsinized (0.25% trypsin), and the cell
mixture was incubated with CD31-coated Dyna-
beads for 30 min at 4°C with end-over-end rotation.
After incubation, the HPAECs were collected using a
magnetic particle concentrator (MCP-1; Dynal) and
washed four times with cold phosphate-buffered
saline (PBS)/bovine serum albumin (BSA). Clusters
of purified HPAECs retained on the CD31-coated
Dynabeads were separately resuspended in EGM-2
full growth medium supplemented with 10% FCS,
1% fungizone and 2% streptomycin/penicillin. The
cells not retained on the CD31-coated Dynabeads
were discarded.
Real time RT-PCR
Total RNA was isolated from cultured HPAECs
by using TriPure® Isolation Reagent (Roche, India-
napolis, USA). Integrity of the extracted RNA was
confirmed with Bioanalizer (Agilent, Palo Alto, CA,
USA). The reverse transcription was performed in
300 ng of total RNA with TaqMan reverse transcrip-
tion reagents kit (Applied Biosystems, Perkin-Elmer
Corporation, CA, USA). cDNA was amplified with
specific primers for ETB and RhoA (pre-designed by
Applied Biosystems, ETB: cat. n°: Hs00240747_m1;
RhoA: cat. na: Hs00357608_m1) and GAPDH (pre-
designed by Applied Biosystems, cat. n°: 4352339E)
as a housekeeping gene in a 7900HT Fast Real-Time
PCR System (Applied Biosystem) using Universal
Master Mix (Applied Biosystems). Relative quantifi-
cation of these different transcripts was determined
with the 2-DDCt method using GAPDH as endoge-
nous control (Applied Biosystems; 4352339E) and
normalized to control group.
Transfection of small interfering RNA
Small interfering RNA (siRNA), including the
scrambled siRNA control, were purchased from
Ambion (Huntingdon, Cambridge, UK). RhoA-
targeted siRNA (ID: s758) sense 5′-CACAGUGUUU
GAGAACUAUtt-3′ and antisense 5′-AUAGUUCUCA
AACACUGUGgg-3′ were designed from Ambion. The
HPAECs were transfected with siRNA (50 nM) in
serum- and antibiotic-free medium, over 6 h. The
medium was then aspirated and replaced with serum
containing medium for a further period of 42 h
before CSE experiments. The transfection reagent
used was lipofectamine-2000 (Invitrogen, Paisley,
UK) at a final concentration of 2 mL·mL-1. The mRNA
expression for RhoA transcript was determined by
real time RT-PCR after 48 h post-silencing and com-
pared with siRNA control at the respective time to
determine silencing efficiency. Furthermore, RhoA
protein expression was measured by Western blot
after 48 h of silencing using a commercial mono-
clonal mouse anti-human RhoA antibody (AbD
serotec, UK, cat. n° MCA5312Z). Protein expression
was referred to b-actin (1:1000, Sigma, USA) expres-
sion as internal control. All experiments were
performed in triplicate.
Western blot
Western blot analysis was used to detect changes in
ETB receptors (50 kD), MLC (18 kD) and RhoA
(22 kD). Cells were scraped from a confluent 25 cm2
flask and lysed on ice with a lysis buffer consisting of
BJPCigarette smoke and endothelin B receptor
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a complete inhibitor cocktail plus 1 mM EDTA
(Roche Diagnostics Ltd, West Sussex, UK) with
20 mM Tris base, 0.9% NaCl, 0.1% Triton X-100,
1 mM dithiothreitol and 1 mg·mL-1 pepstatin A. The
Bio-Rad assay (Bio-Rad Laboratories Ltd, Herts, UK)
was used (following manufacturer’s instructions)
to quantify the level of protein in each sample to
ensure equal protein loading. Sodium dodecyl sul-
phate polyacrylamide gel electrophoresis was used
to separate the proteins according to their molecular
weight. Briefly, 20 mg proteins (denatured) along
with a molecular weight protein marker, Bio-Rad
Kaleidoscope marker (Bio-Rad Laboratories), was
loaded onto an acrylamide gel consisting of a 5%
acrylamide stacking gel stacked on top of a 10%
acrylamide resolving gel and run through the gel by
application of 100 V for 1 h. Proteins were trans-
ferred from the gel to a polyvinylidene difluoride
membrane using a wet blotting method. The mem-
brane was blocked with 5% Marvel in PBS contain-
ing 0.1% Tween20 (PBS-T) and then probed with a
rabbit anti-human ETB receptor (1:1000) antibody
(polyclonal antibody, cat. n°: E9905, Sigma, UK),
rabbit anti-human diphospho-MLC (Thr18/Ser19)
and rabbit anti-human MLC (1:1000) antibodies
(rabbit polyclonal antibodies, cat. n°: 3674 and
3672, Cell signalling), monoclonal mouse anti-
human RhoA (1:1000) antibody (AbD serotec, UK,
cat. n° MCA5312Z) or b-actin (1:1000) as control,
followed by a peroxidase conjugated secondary
(1:10 000) antibody. The enhanced chemilumines-
cence method of protein detection using enhanced
chemiluminescence reagents, ECL plus (Amersham
GE Healthcare, Buckinghamshire, UK) was used to
detect labelled proteins.
Preparation of cigarette smoke
extracts solutions
Cigarette smoke extracts (CSE) were prepared as pre-
viously reported (Ortiz et al., 2009; Milara et al.,
2010). Briefly, the smoke of a research cigarette
(2R4F; Tobacco Health Research, University of
Kentucky, KY, USA) was generated by a respiratory
pump (Apparatus Rodent Respirator 680; Harvard,
Germany) through a puffing mechanism related to
the human smoking pattern (3 puffs·min-1; 1 puff
35 mL; each puff of 2 s duration with 0.5 cm above
the filter) and was bubbled into a flask containing
25 mL of pre-warmed (37°C) EGM-2 medium. The
CSE solution was sterilized by filtration through
a 0.22 mm cellulose acetate sterilizing system
(Corning, NY). The resultant CSE solution was
considered to be 100% CSE and was used for expe-
riments within 30 min of preparation. A dilution
to 10% CSE corresponds approximately to the expo-
sure associated with smoking two packs per day
(Su et al., 1998). The quality of the prepared CSE
solution was assessed based on the absorbance
at 320 nm, which is the specific absorption wave-
length of peroxynitrite. Stock solutions with an
absorbance value of 3.0  0.1 were used. In order to
test for cytotoxicity from CSE, HPAECs were treated
with CSE concentrations of up to 10% for 24
and 48 h. No significant difference in the lactate
dehydrogenase supernatant level (lactate dehyd-
rogenase cytotoxicity assay; Cayman, Spain) was
observed, compared with the control group (data
not shown).
Measurement of intracellular free Ca2+
Intracellular free calcium concentration ([Ca2+]i) was
measured by epifluorescence microscopy (Nikon
TE200, Tokyo, Japan) in HPAECs using the Ca2+ indi-
cator dye fura-2 as previously outlined (Dalli et al.,
2008). In brief, fluorescence of fura-2 acetoxymethyl
ester (5 mM)-loaded cells was measured by using
continuous rapid alternating excitation (340 and
380 nm) and emission (510 nm) in a fluorescence
spectrophotometer equipped with a xenon lamp
(Spectramaster System, Perkin Elmer, Life Sciences,
Cambridge, UK) and a CDD camera CoolSNAPfx
photometrics (20 MHz, 1300 ¥ 1030 pixel). The
fluorescence ratio was recorded every 0.1 s using
Lambda 10-2 Sutter Instrument (Nikon CO. Tokyo,
Japan) and fluorescence analysis was performed
with the software Metafluor® 5.0.
[Ca2+]i was calculated by ratiometric analysis as
outlined (Grynkiewicz et al., 1985). The following
formula was used to convert the fluorescence signal
into [Ca2+]i; [Ca2+]I = b·Kd (R - Rmin/Rmax - R), where R
is the ratio between the fluorescence (F340/F380) at
340 and 380 nm, b is the ratio of 380 nm intensities
at zero Ca2+ over maximal Ca2+ and Kd is the disso-
ciation constant at 224 nM. Background levels of
fluorescence at each excitation wavelength were
determined in cell-free areas and subtracted for each
experiment. Minimum and maximum fluorescence
intensities were obtained with the addition of
Ca2+-free solution with 10 mM EDTA solution and
the Ca2+ ionophore ionomycin 10 mM in presence of
5 mM CaCl2 solution, respectively, as previously
outlined (Dalli et al., 2008; Cortijo et al., 2010). The
experiments performed on intracellular Ca2+
were designed to study the functional effect of the
overexpression of ETB receptors induced by CSE.
Actin staining
Cells were washed three times with PBS and fixed in
a 3.7% formaldehyde-PBS solution for 10 min at
room temperature. After two additional washes with
PBS, cells were permeabilized with a solution of
0.1% Triton X-100 in PBS for 3–5 min and washed
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again with PBS. Phalloidin-tetramethylrhodamine
isothiocyanate (0.2 mg·mL-1) and Alexa Fluor 488
DNase I conjugate (9 mg·mL-1) were used to localize
F-actin and G-actin, respectively, as described by
Cramer et al. (2002). Fluorescent dyes were diluted
on blocking solution (1% BSA and 0.025% saponin
in PBS) and added to coverslips for 40 min at room
temperature. After three washes with PBS, coverslips
were mounted on a microscopy slide with mounting
media (mowiol; Calbiochem, La Jolla, CA). F-actin-
to-G-actin fluorescence ratio was quantified using
fields containing >30 cells imaged with an inverted
fluorescence microscope (Eclipse TE200, Nikon) and
a 12 bit-resolution cooled-charge-coupled device
camera (CoolSNAPfx photometrics) at ¥10 magnifi-
cation. Time of image acquisition and image inten-
sity gain were optimally adjusted and kept constant
for all experiments with the software Metafluor® 5.0.
F- and G-actin cytoskeleton imaging was performed
with an epifluorescence microscope ((Nikon TE200,
Tokyo, Japan) at ¥40 magnification.
Cell contraction
Contraction of HPAECs in response to ET-1
was studied by traction microscopy as previously
outlined (Cortijo et al., 2010). Collagen-coated poly-
acrylamide gels with embedded fluorescent micro-
beads (200 nm diameter) were used. Gel disks with
cultured HPAECs were incubated for 24 h in absence
(control) or presence of CSE 10% alone or in com-
bination (1 h before CSE) with bosentan, BQ788,
ML-7 or Y27632. Then, a gel disk with cultured
HPAECs was placed in the microscope and
cells examined with bright-field illumination. After
5 min of baseline recording, ET-1 (10 nM) was
added, and fluorescent images were acquired for an
additional 10 min. Traction forces exerted by the
cell on the substrate were computed from the dis-
placement field of the gel substrate (Cortijo et al.,
2010). Measurements were taken in 10 cells from
different cell-gel samples for different conditions.
Rho activity assays
A commercially available, enzyme-linked immun-
osorbent assay (ELISA)-based RhoA activity assay
(G-LISA; Cytoskeleton, Denver, CO) was used to
measure the relative RhoA activity of serum-starved
HPAECs after experimental treatments. Whole cell
lysates were processed with the G-LISA protocol,
using the lysis buffer provided in the kit. The lysates
were incubated in microwells to which the rhotekin
binding domain peptide was bound, and active
RhoA was detected using indirect immunodetection
followed by a colorimetric reaction measured by
absorbance at 490 nm.
ET, NO and TxA2 production
Endothelin was measured in HPAEC culture super-
natants by enzyme immune assay kit (Cayman
chemical, USA) according to the manufacturer’s pro-
tocol. NO was measured as nitrites in HPAEC culture
supernatant samples, using a commercially available
nitric oxide assay kit (Calbiochem-Novabiochem,
San Diego, CA) according to the manufacturer’s
protocol. TxA2 was measured as TxB2 (a stable
metabolite of TxA2) in HPAEC culture supernatants
by enzyme immune assay kit (Cayman chemical,
USA) according to the manufacturer’s protocol.
Fluorescence measurement of ROS
The fluorogenic substrate 2′, 7′-dichlorofluorescein
diacetate (DCFDA, Molecular proves, UK) is a cell-
permeable dye that is oxidized to highly fluorescent
2′, 7′-dichlorofluorescein (DCF) by O2- and H2O2,
and can therefore be used to monitor intracellular
generation of ROS. To quantify ROS levels, HPAECs
were seeded to black walled, clear bottom 96 well
plates, washed twice with PBS and incubated for
30 min with 50 mM DCFDA diluted in Opti-MEM
with 10% FCS. At the end of the incubation period,
the cells were again washed twice with PBS and
stimulated with ET or CSE. Then, fluorescence was
measured using a microplate spectrophotometer
(Victor 1420 Multilabel Counter, PerkinElmer) at
excitation and emission wavelengths of 485 and
528 nm, respectively, at 5 min intervals for a total of
45 min. Results were expressed as DFC fluorescence
in relative fluorescence units versus time (min).
Immunofluorescence
Human pulmonary artery endothelial cells were
washed three times with PBS and fixed (4%
paraformaldehyde, 30 min, at room temperature).
After another three washes with PBS, HPAECs were
permeabilized (20 mM HEPES pH 7.6, 300 mM
sucrose, 50 mM NaCl, 3 mM MgCl2, 0.5% Triton
X-100), blocked (10% goat serum in PBS) and incu-
bated with the primary antibody, rabbit anti-human
ETB receptor (1:100, cat. n°: E9905, Sigma) overnight
at 4°C, followed by secondary antibody anti-rabbit
rhodamine (1:100, Molecular Probes) and DAPI
(2 mg/mL) to mark nuclei (Molecular Probes, Leiden,
The Netherlands). Cells were visualized by epifluo-
rescence microscopy (¥200; Nikon eclipse TE200
inverted microscope, Tokyo, Japan).
Experimental protocols
The experiments performed on cell contraction,
intracellular Ca2+, F/G-actin, RhoA activity and MLC
phosphorylation, NO and TxA2 production and ROS
production were designed to study the functional
BJPCigarette smoke and endothelin B receptor
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effect of the overexpression of ETB receptors induced
by CSE. For this, HPAECs were treated with or
without CSE for 24 h in presence or absence of
bosentan or different pharmacological modulators
(added 1 h before CSE). Then, HPAECs were washed
three times with PBS and stimulated with exog-
enous ET-1 (10 nM) for different times to mimic the
lung microenvironment associated with PH where
ET is highly elevated (Holm and Franco-Cereceda,
1996; Cacoub et al., 1997). At the end of the ET-1
stimulation, the variables described above were
measured and compared with corresponding values
from cells not exposed to CSE.
Statistical analysis
Data are presented as mean  SEM of n experi-
ments. Statistical analysis of data was carried out by
analysis of variance (ANOVA) followed by Bonferroni
test (GraphPad Software Inc, San Diego, CA, USA).
Every experiment showed in this study was per-
formed in HPAECs from at least three different
patients in three to four experiments per patient.
Significance was accepted when P < 0.05.
Materials
Unless stated otherwise, all reagents used were
obtained from Sigma Chemical Co. (Madrid, Spain).
Bosentan (provided by Actelion Pharmaceuticals
Ltd), BQ788, ML-7 and N-acetylcysteine (NAC) were
dissolved in dimethyl sulphoxide as 10 mM stock
solutions. Several dilutions of the stock solutions
were prepared, using cell culture medium. The final
concentration of dimethyl sulphoxide in the culture
medium did not exceed 0.01% and had no signifi-
cant pharmacological activity. ET-1 and Y27632
were dissolved in sterile water. Mouse monoclonal
antibody against human ET-1 (mAb-ET-1) (Abcam;
cat. n°: ab20940) was used at 10 mg·mL-1 concentra-
tion to suppress the effect of ET-1 released into cell
supernatants, as previously outlined (Didier et al.,
2003). Non-specific mouse IgG1 was used at the
same concentration as control.
Results
CSE-induced up-regulation of ETB receptors in
HPAECs is partly suppressed by bosentan
Cigarette smoke extract dose-dependently increa-
sed ETB receptor mRNA and protein expression
in HPAECs after 24 h of incubation (Figure 1A).
Interestingly, the overexpression of ETB receptors
induced by CSE was inhibited by bosentan in a
concentration-dependent manner (10 nM–10 mM;
Figure 1B), reaching statistical significance at
100 nM (Figure 1B, P < 0.05 vs. CSE 10%). In
addition, the selective ETB receptor antagonist
BQ788 also reduced, in a concentration-dependent
manner, the ETB receptor overexpression (10 nM–
10 mM; Figure 1C), suggesting a feed forward mecha-
nism mediated via ET receptors. These results were
also confirmed by immune-fluorescence staining
with ETB receptor antibody (Figure 1D). Incubation
with bosentan or BQ788 alone did not show any
effect on basal ETB receptor expression (data not
shown). To elucidate further the mechanisms
involved in the CSE-induced ETB overexpression,
the amount of ET in cell culture supernatants were
measured. CSE dose-dependently released ET from
HPAECs, reaching statistical significance at 5%–10%
concentrations (Figure 2A, P < 0.05 vs. basal condi-
tions). Furthermore, the addition of mAb to ET-1
(10 mg·mL-1), significantly reduced the overexpres-
sion of ETB receptors induced by CSE suggesting
that the ET-1 released by CSE was involved in this
process (Figure 2B, P < 0.05 vs. CSE 10%). Interest-
ingly, stimulation of HPAECs with exogenous ET-1
dose-dependently (100 pM–100 nM) also increased
ETB receptor expression. These results demonstrate
that ET-1 is one of the downstream effectors of CSE
causing ETB receptor overexpression.
Overexpression of ETB receptors induced by
CSE is partly mediated by the activation of
ETB and the downstream pathway Rho kinase
and ROS production
As CS is known to promote RhoA and MLCK acti-
vation and ROS production, we studied the effect of
these downstream pathways on the overexpression
of ETB receptors induced by CSE. The Rho kinase
inhibitor, Y27632 (10 mM) and the antioxidant NAC
(1 mM) effectively reversed the stimulation of
mRNA and protein for ETB receptors induced by CSE
(Figure 3A). In contrast, the MLCK inhibitor ML-7
did not show any significant effect (Figure 3A).
When ET-1 (10 nM) was used to induce ETB receptor
expression, bosentan (10 mM), BQ788 (1 mM),
Y27632 (10 mM), the antioxidant NAC (1 mM) but
not ML-7 partly suppressed the ETB receptor overex-
pression (Figure 3B) suggesting a role for ET-1 in
CSE-induced ETB receptor up-regulation.
In other experiments we explored the possible
additive effects of bosentan, Y27632 and NAC. We
selected concentrations of bosentan (100 nM),
Y27632 (1 mM) and NAC (100 mM), which caused
~50% inhibition of the maximal effect of CSE
(Figure 3C). The combination of these three inhibi-
tors showed an additive effect in reducing the ETB
receptor up-regulation, following CSE (Figure 3C, P
< 0.05 vs. bosentan, Y27632 and NAC groups).
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In order to investigate further the role of RhoA in
our model, we selectivity antagonized RhoA RNA.
siRNA targeted at RhoA produced a marked inhibi-
tion in mRNA and protein expression following
48 h exposure to 50 nM siRNA-RhoA (Figure 3D, P <
0.05 vs. siRNA control). This treatment also pre-
vented the CSE from inducing overexpression of ETB
receptors, confirming the results observed with
Y27632 (10 mM) (Figure 3E, P < 0.05 vs. siRNA
control plus CSE 10%).
Exposure of HPAECs to CSE increased
sensitivity to raised [Ca2+]i induced by ET-1
[Ca2+]i modulates several cellular process such as
endothelial cell contraction and permeabilization,
proliferation and inflammation (Garcia et al., 1993).
As CSE increases ETB receptor expression, we inves-
tigated the effect of acute exposure to exogenous
ET-1 on [Ca2+]i in HPAECs pretreated for 24 h with or
without CSE in presence or absence of bosentan
Figure 1
Cigarette smoke extract (CSE)-induced ETB expression in human pulmonary artery endothelial cells (HPAECs) is attenuated by bosentan. HPAECs
were incubated with different CSE concentrations for 24 h. (A) Then, mRNA and protein for ETB receptors were quantified by real time RT-PCR and
Western blot respectively. (B, C) HPAECs were incubated with bosentan (10 nM–10 mM) or BQ788 (10 nM–10 mM) 1 h before CSE addition.
Bosentan and BQ788 dose-dependently attenuated ETB receptor mRNA and protein expression, as measured by real time RT-PCR and Western
blot. (D) Immunofluorescence for ETB receptors showed an increment of ETB receptor expression (red colour) in cells exposed to CSE, which was
prevented by bosentan (DAPI-blue colour represents nucleus). Scale bar: 10 mm. Results are the mean  SEM of four different experiments from
three different patients per condition. *P < 0.05 versus basal conditions; #P < 0.05 versus CSE 10%.
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(10 mM) or BQ788 (1 mM). Preliminary experiments
showed that ET-1 increased [Ca2+]i in HPAECs in a
dose-dependent manner (-logEC50 = 7.62  0.06,
data not shown). Therefore, a concentration of
10 nM ET-1 was used in subsequent experiments.
HPAECs stimulated with CSE (10%) for 24 h showed
a [Ca2+]i baseline of 120  5 nM, which is signifi-
cantly higher than that observed for unstimulated
cells ([Ca2+]i baseline of 93  3 nM; P < 0.05). Fur-
thermore, stimulation with ET-1 (10 nM, over
3–4 min) increased [Ca2+]i (shown as D[Ca2+]i) in
CSE-treated cells more than in untreated cells (P <
0.05) (Figure 4A,B and Table 1). In other experi-
ments, bosentan (0.1–10 mM) or BQ788 (1 mM) was
added 1 h before incubation with 10% CSE, for a
further 24 h. Under these conditions, bosentan
(1–10 mM) and BQ788 (1 mM) significantly reduced
the effect of subsequent stimulation with exogenous
ET-1 (10 nM) on [Ca2+]i (Figure 4A,B and Table 1,
P < 0.05).
ET-1 increases cell contraction and F/G-actin
imbalance in HPAECs pretreated with CSE
In order to assess whether the increased sensitivity
to ET-1-induced [Ca2+]i was translated into cell con-
traction, we employed traction microscopy tech-
nique. ET-1 (10 nM) produced a fast and sustained
increase in cell contraction that was significantly
higher in those cells exposed to CSE (10%) for 24 h
versus unexposed cells (Figure 5A, P < 0.05). Further-
more, those cells pretreated with CSE in the pres-
ence of bosentan (10 mM), BQ788 (1 mM), Y27632
(10 mM) or ML-7 suppressed cell contraction almost
to control levels (Figure 5A).
Cytoskeletal rearrangement is a direct marker
of cell contraction and polymerization of soluble
G-actin to F-actin fibres is a part of such rearrange-
ment (Gavara et al., 2006). The F/G-actin fluores-
cence ratio value of HPAECs exposed to CSE 10%
for 24 h was not different from that in cells without
CSE (Figure 5B). In contrast, the CSE-treated cells
showed an increased F/G-actin ratio in response
to acute stimulation with ET-1 (10 nM; 30 min)
(Figure 5C, P < 0.05). The addition of bosentan (0.1–
10 mM), BQ788 (1 mM), Y27632 (10 mM) or ML-7
(10 mM) 1 h before CSE (10%) significantly reduced
this increase of F/G-actin ratio induced by ET-1
(Figure 5C, P < 0.05 vs. CSE).
Because Y27632 and ML-7 attenuated the effects
of CSE on ET-1-induced cell contraction, we
explored the activation of RhoA and the phospho-
rylation of MLC in those cells exposed to CSE. In
HPAECs, the basal RhoA activity and MLC phospho-
rylation was not affected by CSE (10%; 24 h;
Figure 6A,B). However, exogenous ET-1 (10 nM,
30 min) increased RhoA activity more in cells
exposed to CSE, than in cells without CSE
(Figure 6C, P < 0.05). Furthermore, when bosentan
(1 and 10 mM), BQ788 (1 mM) and Y27632 (10 mM)
were added before CSE (for 24 h), the ET-1-induced
Figure 2
Cigarette smoke extract (CSE)-induced ETB receptor overexpression is partly mediated by ET in cell supernatants. (A) CSE dose-dependently
releases ET to cell culture supernatant after 24 h of CSE exposure. (B) CSE-induced ETB receptor overexpression was partly inhibited by mAb to
ET-1 (10 mg·mL-1) and not by the isotype IgG1 control (10 mg·mL-1). (C) Furthermore, incubation of human pulmonary artery endothelial cells
(HPAECs) with ET-1 for 24 h dose-dependently increased ETB receptor mRNA and protein expression. Results are the mean  SEM of four different
experiments from three different patients per condition. *P < 0.05 versus basal conditions; #P < 0.05 versus CSE 10%.
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Figure 3
Cigarette smoke extract (CSE)-induced ETB receptor overexpression is attenuated by the blockade of ETB receptors, Rho kinase or reactive oxygen
species (ROS). (A) Human pulmonary artery endothelial cells (HPAECs) were incubated with bosentan, Y27632, NAC or ML-7 for 1 h before the
addition of CSE 10%. After 24 h of incubation, ETB receptor mRNA and protein were quantified by real time RT-PCR and Western blot respectively.
(B) HPAECs were incubated with bosentan, BQ788, Y27632, NAC or ML-7 1 h before the addition of ET-1 (10 nM). After 24 h of incubation, ETB
receptor mRNA and protein were quantified. (C) Additive effects of bosentan, Y27632 and NAC at ~50% effective concentrations showed additive
effects on the inhibition of CSE-induced ETB receptor up-regulation. (D) Specific siRNA targeted to RhoA effectively suppressed RhoA mRNA and
protein expression in HPAECs. (E) siRNA-RhoA suppressed the overexpression of ETB receptors induced by CSE in HPAECs (presented as mRNA and
protein expression), compared with cells transfected with a negative control siRNA. Results are the mean  SEM of three different experiments
from three different patients per condition. *P < 0.05 versus control; #P < 0.05 versus CSE 10%.
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RhoA activity was decreased (Figure 6C, P < 0.05 vs.
CSE). Similarly, CSE (10%) increased the effect of
ET-1 on MLC phosphorylation and this was attenu-
ated by bosentan (10 mM), BQ788 (1 mM), Y27632
(10 mM) or ML-7 (10 mM) (Figure 6D).
ET-1 reduces NO release and increases TxA2
in HPAECs pretreated with CSE
It is well established that CS reduces NO and
increases the release of TxA2; however, no data have
been reported concerning the influence of CS on
ET-1-induced NO and TxA2 release. As CSE increased
ETB receptor expression, the effects of ET-1 on NO
and TxA2 release could be different. Therefore,
HPAECs were exposed to CSE for 24 h and were then
stimulated with ET-1 (10 nM) for 1 h. After stimula-
tion, the stable derivatives of NO and TxA2, namely
nitrites and TxB2, were measured in the cell culture
supernatant. We observed that CSE treatment
reduced the ET-1-induced nitrite release by ~50%
compared with untreated cells (Figure 7A, P < 0.05).
Furthermore, addition of bosentan (1 and 10 mM),
Figure 4
Exposure of human pulmonary artery endothelial cells (HPAECs) to cigarette smoke extract (CSE) for 24 h increased the rise in [Ca2+]i induced by
ET-1. (A) HPAECs were exposed to vehicle, bosentan or BQ778 for 24 h. Then cells were washed three times with PBS and incubated with Fura
2AM. The increase of [Ca2+]i following acute stimulation with ET-1 (10 nM), was the same for each condition. (B) HPAECs were exposed to 10%
CSE, in presence or absence of bosentan or BQ778 for 24 h. Then cells were washed three times with PBS and incubated with Fura 2AM. The
increase of [Ca2+]i following acute ET-1 (10 nM) was higher in the cells exposed to 10% CSE. Results are the mean  SEM of [Ca2+]i nM in 12 cells
per experiment in a total of four experiments per condition.*P < 0.05 versus control; #P < 0.05 versus CSE 10%.
Table 1
Exposure of HPAECs to CSE for 24 h increased the rise in [Ca2+]i induced by acute stimulation by exogenous ET-1
24 h pretreatment
Acute ET-1 10 nM stimulation
D[Ca2+]i (nM) AUC [ [Ca2+]i (nM) ¥ seconds]
Control 143  6 20730  997
CSE 10% 215  13* 25056  994*
Bosentan 10 mM + CSE 10% 133  11# 20221  803#
Bosentan 1 mM + CSE 10% 154  8# 21311  925#
Bosentan 0.1 mM + CSE 10% 201  12 243111032
BQ788 1 mM + CSE 10% 144  7# 208551090#
Bosentan 10 mM 135  6 20337  1175
BQ788 1 mM 132  16 20968  488
HPAECs were incubated for 24 h with or without CSE 10%, bosentan, BQ788 and their different combinations. After 24 h, culture medium
was removed and cells were washed three times with PBS. Then, cells were loaded with Fura 2AM and [Ca2+]i was monitored following
stimulation with ET-1 (10 nM). Results are the mean  SEM of the rise in [Ca2+]i (D[Ca2+]i; nM) or area under curve (AUC; nM ¥ seconds) of
D[Ca2+]i in 12 cells per experiment in a total of four experiments per condition.
*P < 0.05 versus control; #P < 0.05 versus CSE 10%.
HPAECs, human pulmonary artery endothelial cells; CSE, cigarette smoke extract.
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BQ788 (1 mM), Y27632 (10 mM) or the antioxi-
dant NAC (1 mM) significantly increased nitrite
release following ET-1 (Figure 5A, P < 0.05 vs. CSE).
In contrast, ML-7 (10 mM) failed to modify NO
release. Conversely, in HPAECs treated with CSE,
TxB2 release induced by ET-1, was increased by
approximately twofold (Figure 5B, P < 0.05 vs. unex-
posed cells to CSE). Bosentan (1 and 10 mM), BQ788
(1 mM), Y27632 (10 mM) and NAC (1 mM) signifi-
cantly reduced the TxB2 release by ET-1 (Figure 5A,
P < 0.05 vs. CSE), while ML-7 did not show any
effects.
Figure 5
ET-1 increases cell contraction and F/G-actin imbalance in human pulmonary artery endothelial cells (HPAECs) pretreated with cigarette smoke
extract (CSE). (A) Disks with cultured HPAECs were incubated for 24 h in absence (control) or presence of CSE (10%) alone or in combination (1 h
before CSE) with bosentan, BQ788, ML-7 or Y27632. Then, a gel disk with cultured HPAECs was placed in the microscope and cells imaged with
bright-field illumination. The graph shows the time course of contractile response of HPAECs challenged with ET-1 (10 nM). Values are expressed
as total force exerted by the cell on the substrate. (B) HPAECs were treated with or without CSE for 24 h. Then, cells were fixed with 3.7%
formaldehyde and phalloidin-tetramethylrhodamine isothiocyanate and Alexa Fluor 488 DNase I conjugate were added to mark F- and G-actin
respectively. DAPI was added to mark cell nucleus. Images are representative of the F-actin (red colour) and G-actin (green colour) staining, and
the graph shows the basal F/G-actin fluorescence ratio after these experimental conditions. (C) In other experiments, bosentan, BQ788, Y27632
or ML-7 were added to cell culture 1 h before CSE. After 24 h of incubation cells were washed three times with PBS and stimulated with ET-1
10 nM for 30 min. Then, cells were treated to mark F- and G-actin. DAPI was added to mark cell nucleus (blue colour). HPAECs images show
representative experiments under these experimental conditions. Scale bar: 10 mm. The graph shows the mean  SEM of the fluorescence
intensities of F-actin (red) versus G-actin (green) in a total of three different experiments from three different patients per condition. *P < 0.05
versus control; #P < 0.05 versus CSE.
BJPCigarette smoke and endothelin B receptor
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ET-1 increases intracellular ROS production
in HPAECs pretreated with CSE
Reactive oxygen species are purported to be the
main initiator of intracellular reactivity in endothe-
lial cells exposed to CS. Thus, we examined endot-
helial ROS production in response to CSE and found
that CSE increased intracellular ROS in a time and
concentration-dependent manner, reaching a peak
value after 10 min of stimulation (Figure 8A). This
maximum was followed by a subsequent decline
that plateaued above baseline levels after ~30 min
(Figure 8A). The antioxidant NAC (1 mM) com-
pletely prevented ROS generation (Figure 8A).
Second, we studied the role of CSE on ROS produc-
tion induced by exogenous ET-1. As ET-1 (10 nM)
induced submaximal ROS production after 10 min
of stimulation (Figure 8B), we selected these experi-
mental conditions in further experiments. HPAECs
stimulated with CSE (10%) for 24 h showed an
increase of ROS production in response to exog-
enous ET-1, which was significantly higher than in
HPAECs not exposed to CSE (Figure 6C, P < 0.05 vs.
unexposed cells). When bosentan (1 and 10 mM),
BQ788 (1 mM), Y27632 (10 mM) and NAC (1 mM)
were added to HPAECs before CSE, the effect of ET-1
on ROS production was suppressed (Figure 8C, P <
0.05 vs. CSE).
Discussion
This study was designed to evaluate the effect of CS
on ETB receptor expression in HPAECs and to
examine the functional consequences in the
context of ET-1 exposure in vitro. We found for the
first time that HPAECs stimulated with CSE increase
ETB receptor expression via a feed forward mecha-
nism involving ET release from CSE-exposed cells.
Moreover, bosentan as well as the selective ETB
receptor inhibitor BQ788 prevented the overexpres-
sion of ETB receptors induced by CSE. Furthermore,
such overexpression sensitized HPAECs to ET-1
Figure 6
Exposure of human pulmonary artery endothelial cells (HPAECs) to cigarette smoke extract (CSE) sensitizes cells to ET-1-induced RhoA activation
and myosin light chain (MLC) phosphorylation. (A) RhoA activation was measured in HPAECs, with or without CSE treatment (10% for 24 h) by
commercial colorimetric kit. (B) After 24 h of CSE exposure MLC phosphorylation was measured by Western blot. (C, D) HPAECs were incubated
with CSE for 24 h. After CSE treatment cells were washed three times with PBS and stimulated with ET-1 10 nM for 30 min, and RhoA activity (C)
and MLC phosphorylation (D) were measured. Cells exposed to CSE showed an increase of RhoA activity and p-MLC compared with cells not
exposed. Furthermore, incubation with bosentan, BQ788, Y27632 or ML-7 (only in p-MLC experiments) 1 h before CSE addition, attenuated the
ET-1-induced RhoA activation and MLC phosphorylation. Results are the mean  SEM of the absorbance corresponding to active RhoA and
representative Western blot for p-MLC in a total of three different experiments from three different patients per condition. *P < 0.05 versus control;
#P < 0.05 versus CSE 10%.
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stimulation, thereby causing endothelial dysfun-
ction, as shown by increased cell contraction;
reduced NO synthesis and increased production of
TxA2 and of ROS. These results suggest that CS exerts
pro-inflammatory effects by the up-regulation of ETB
receptors, potentiating endothelial dysfunction
induced by ET-1.
Recent studies focussing on ETB receptor func-
tion in endothelial cells suggest a protective role,
as its stimulation released vasodilators and anti-
angiogenic factors such as NO and PGI2. Moreover,
it has been shown that endothelial ETB receptor
knockout mice develop severe right ventricular pres-
sure during hypoxia (Kelland et al., 2010), and that
endothelial ETB receptors remove ET-1 from the sys-
temic circulation into lung tissue. In contrast to ETA
receptors, the ETB receptors are inducible proteins in
both smooth muscle cells and endothelial cells
(Galie et al., 2004; Yeligar et al., 2009). However,
in thromboembolic PH and in PH derived from
systemic sclerosis as well as in inflammatory con-
ditions, ETB receptor expression is up-regulated
mainly in pulmonary arterial smooth muscle cells
where ETB receptors mediate contraction and
smooth muscle cell proliferation (Bauer et al., 2002;
Frommer and Muller-Ladner, 2008) thereby con-
tributing to pulmonary remodelling. Furthermore,
CS also up-regulates ETB receptor expression in
Figure 7
Exposure of human pulmonary artery endothelial cells (HPAECs) to
cigarette smoke extract (CSE) increased the imbalance between NO
and TxA2 release in response to acute ET-1. HPAECs were cultured in
six well flasks until ~95% confluent. Then, cells were incubated with
or without CSE 10% for 24 h. In parallel experiments, bosentan,
BQ788, Y27632, NAC or ML-7 were added to cell cultures, 1 h
before CSE. After 24 h of incubation, cells were washed three times
with PBS and stimulated with ET-1 for 30 min. CSE-treated cells
released less NO (measured as nitrites) (A) and more TxA2 (measured
as TxB2) (B), in response to acute ET-1. Furthermore, cell incubation
with bosentan, BQ788, Y27632 or NAC attenuated the effect of CSE
on ET-1-induced NO decrease and TxA2 increase. Results are the
mean  SEM of a total of three different experiments from three
different patients per condition. *P < 0.05 versus control; #P < 0.05
versus CSE 10%.
Figure 8
ET-1 increases reactive oxygen species (ROS) production in human
pulmonary artery endothelial cells (HPAECs) treated with cigarette
smoke extract (CSE). (A, B) Confluent HPAECs were cultured in black
walled, clear bottom, 96 well plates and loaded with DCFDA for
30 min. Then, cells were exposed to (A) CSE (2.5%–10%) or (B) ET-1
(0.1–100 nM) and DCF fluorescence was monitored every 5 min
during 45 min. (C) In other experiments, cells were incubated with
or without CSE 10% in presence or absence of bosentan, BQ788,
Y27632, NAC or ML-7 for 24 h. Then, cells were washed three times
with PBS and loaded with DCFDA for 30 min. Cells were stimulated
with ET-1 (10 nM) and DCF fluorescence was measured after 10 min
of stimulation. Results are the mean  SEM of a total of six different
experiments from three different patients per condition. *P < 0.05
versus control; #P < 0.05 versus CSE 10%.
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pulmonary artery smooth muscle cells causing
pulmonary artery contraction (Xu et al., 2008).
However, the role of CS on ETB receptor expression
and its functional consequences in endothelial cell
function remain to be elucidated.
In this work we focused on the effect of CS as an
inflammatory stimulus, which could be a primary
agent in the initial endothelial damage that could
induce PH in COPD patients. We found that CSE
induced ETB receptor overexpression in HPAECs
and that this was prevented by the ETB/ETA receptor
antagonist bosentan, the selective ETB receptor
antagonist BQ788 as well as by the inhibition of Rho
kinase and ROS. It is known that CS induces RhoA
activation and ROS generation in endothelial cells,
promoting endothelial dysfunction (Sugimoto et al.,
2007; Richens et al., 2009; Milara et al., 2010), and
that ROS generation may up-regulate ETB receptor
expression (Yeligar et al., 2009). As CSE induces ET
release (Wright et al., 2006), and the activation of
ETB receptors induces ROS production (Dong et al.,
2005), it seems reasonable to suggest that bosentan
and BQ788 may inhibit the overexpression of ETB
receptors induced by CSE. Indeed, we detected an
increased ET concentration following CSE exposure.
Furthermore, the addition of mAb to ET-1 partially
suppressed the CSE-induced ETB receptor overex-
pression. This finding was reinforced by evidence
that ETB receptors were up-regulated by ET-1, sug-
gesting that the CSE-induced overexpression of ETB
receptors is mediated, in part, by a feed forward
mechanism.
Although the expression of ETB receptors in
endothelial cells is thought to be associated with
beneficial effects, its overexpression in an inflamma-
tory context has not been fully examined. Thus, we
investigated the functional role of the overexpres-
sion of ETB receptors induced by CSE in HPAECs.
Endothelial permeability may be an important
component of the pathogenesis of PH, because it
increases infiltration of inflammatory cells into the
wall of pulmonary arteries, thereby enlarging the
intimal layer and promoting pulmonary remo-
delling. In this context, it has been suggested that
the development of structural and functional abnor-
malities in pulmonary arteries of patients with
COPD is related to inflammatory cell invasion of the
vascular wall by inflammatory cells (Wright et al.,
2005).
The GTPase RhoA and the myosin kinase MLCK
play a key role in cell contraction and permeability
(Oka et al., 2008). Stimulation of ETB receptors
induces RhoA activation and intracellular Ca2+
release, and both mediate MLC phosphorylation,
which increases formation of F-actin stress fibres,
cell contraction and permeability (Oka et al., 2008;
Morrell et al., 2009). Consistent with these findings,
in vivo studies have shown that selective ETB recep-
tor activation increased albumin extravasation in
guinea pig lungs (Filep et al., 1995). In this work, we
observed that CSE-induced overexpression of ETB
receptors in HPAECs sensitizes these cells to acute
stimulation by exogenous ET-1. Thus, CSE-exposed
cells showed an increased effect of acute ET-1 in
responses associated with cell permeability such as
the increase of [Ca2+]i, RhoA activation, MLC phos-
phorylation, F-actin polymerization and cell con-
traction. As pre-incubation with bosentan, BQ788
and Y27632 reduced these effects and prevented the
ETB overexpression, we would suggest that ET-1-
induced endothelial permeability in cells exposed to
CSE was mediated, in part, by the induction of ETB
receptor expression.
Next, we focused on the effect of exposure to CSE
in terms of NO and TxA2 release induced by ET-1.
The balance of the vasodilator/vasoconstrictor cell
release is a key regulator of endothelial cell function.
Under physiological conditions, HPAECs mainly
release the vasodilator and anti-angiogenic agents,
NO and PGI2. However, during cell injury, this
balance may be altered thereby promoting the
release of vasoconstrictors (Christman et al., 1992).
There is strong evidence that part of the ET-1-
induced vasoconstriction is mediated by increased
TxA2 production, which, in turn, is mediated by
the ETB receptors in the vascular endothelium
(D’Orleans-Juste et al., 1994; Curzen et al., 1995).
The endothelial ETB receptors may thus have a
dual role, modulating both vasoconstriction and
vasodilation, and these effects could, in turn, be
modulated by pathological conditions affecting
endothelial function itself. In the present work we
observed that treatment of HPAECs with CSE sensi-
tized these cells to produce less NO and more TxA2
in response to acute ET-1. Furthermore, this effect
was attenuated by bosentan, BQ788, Y27632 and
NAC, suggesting that ETB receptors, Rho kinase and
ROS were involved in this process.
It is well established that CS inhibits eNOS activ-
ity and reduces NO bioavailability through the
interaction of NO with ROS to form peroxynitrite.
Furthermore, as we have commented before, CSE
induces RhoA and the downstream Rho kinase acti-
vation that can directly phosphorylate eNOS at
Thr459 to suppress NO production in endothelium
(Sugimoto et al., 2007). Intracellular ROS produced
by CSE and ET-1 could explain, in part, the imba-
lance between the vasodilator/vasoconstrictor
release. Thus, ET-1-induced ROS production was
highest in HPAECs exposed to CSE suggesting that
ETB receptor overexpression increased ROS produc-
tion. Furthermore, bosentan, BQ788, Y27632 and
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NAC completely suppressed the effect of CSE on
ET-1-induced ROS. As these compounds also pre-
vented the overexpression of ETB receptors second-
ary to CSE, we would postulate that the ET-1-
induced ROS in CSE-exposed cells is mediated, at
least in part, by ETB receptor overexpression.
In summary, we would like to propose a model in
which CSE induces ETB receptor overexpression by a
feed forward mechanism mediated in part by release
of ET from the cells, promoting HPAEC dysfunction,
which is partly attenuated by blockade of ETB recep-
tors, Rho kinase and ROS. These results may provide
in vitro evidence supporting the use of bosentan in
CS-related endothelial dysfunction.
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